Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Pan American Silver Corp. Common Stock (PAAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Pan American Silver Corp. Common Stock — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Pan American Silver Corp. Common Stock trades at $42.71 (market cap $18.39B). The key difference: Pan American Silver Corp. Common Stock is far larger — about 18.9× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Pan American Silver Corp. Common Stock pays a 1.65% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Pan American Silver Corp. Common Stock for 2 Days on average.
| MRVI | PAAS | |
|---|---|---|
Market Cap | $972.90M | $18.39B |
Volume | 4,325,710 | 3,168,808 |
Sector | Health | Basic Materials |
52-Week High | $9.00 | $68.70 |
52-Week Low | $2.83 | $33.20 |
Typical Hold Time | 0 Days | 2 Days |
Enterprise Value | $1.08B | $17.52B |
Dividend Yield | — | 1.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Pan American Silver (PAAS) trades at $44.53, down 2.58% on the day, with a bearish technical signal from moving averages. The company reported strong 2025 results with $978M net income and a 32.03% net margin, and analysts project 2026 revenue growth to $4.3B. Recent news highlights growth from the Timmins and La Colorada projects and a director retirement effective October 31, 2026.
The outlook is positive with a consensus price target of $62.50, implying 40% upside, supported by solid cash flow and reserve growth. Risks include silver price volatility and potential cost pressures. Analyst sentiment is bullish with 52% buy ratings, but technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Pan American Silver Corp. Common Stock
Pan American Silver is a mining company focused on silver and gold production in the Americas. It also explores and develops precious metals properties.
Read more on PAAS →
